Best Value Stocks to Buy for September 11th

Zacks highlighted Qifu Technology (QFIN), AXIS Capital (AXS), and Mitsui & Co. (MITSY) as Rank #1 value stocks, citing upward current-year earnings-estimate revisions of 20.5%, 6.7%, and 5.9%, respectively, over the past 60 days. Each trades at a substantial discount to its industry P/E: QFIN at 5.03x versus 63.00x, AXS at 7.18x versus 15.70x, and MITSY at 9.80x versus 20.50x. The article is favorable analyst commentary but does not contain company-reported earnings, guidance, or material corporate developments.

Analysis

This is a low-information screening signal rather than a discrete fundamental catalyst; estimate revisions and low headline P/E can persist without rerating. QFIN's discount is principally a China consumer-credit and ADR governance risk premium, not an obvious mispricing versus U.S. fintech peers. The key earnings sensitivity is credit performance: incremental loan originations only support equity value if take rates hold and delinquency/vintage losses do not consume the apparent operating leverage.

AXS is the cleaner institutional expression of the screen. A specialty insurer can compound book value through disciplined underwriting and investment income, but the valuation gap will only close if management sustains favorable accident-year loss ratios while returning capital; one large catastrophe or adverse reserve development can erase several quarters of estimate momentum. Relative to broad insurers, AXS has more exposure to the reinsurance pricing cycle, making January renewals and third-quarter reserve commentary the relevant 1-3 month catalysts.

MITSY is omitted from the supplied ticker set, but its presence highlights that the recommendation is factor-driven rather than theme-driven. For QFIN, a 6-18 month rerating requires evidence that China’s consumer-credit cycle is stabilizing and capital-return policy remains credible; absent that, low multiples may be a permanent feature. Contrarian view: the market is more likely underpricing AXS underwriting durability than QFIN's political and credit-tail risks, so equal-weighting these "value" names is not justified.

Key Decisions for Investors

• Initiate a 3-6 month long AXS position versus short KIE or a diversified U.S. insurance basket; target 10-15% relative upside if reserve development remains benign and January reinsurance pricing stays firm. Exit on material adverse reserve development, a combined-ratio miss versus guidance, or evidence of weakening renewal rates.
• Keep QFIN on a watchlist rather than treat the low P/E as a standalone long signal. Upgrade only after quarterly disclosures show stable or improving delinquency/vintage trends, loan facilitation growth, and no deterioration in funding economics; these data are required to distinguish a true earnings rerating from late-cycle credit risk.
• For investors requiring China-fintech exposure, size QFIN at roughly half a comparable developed-market financial position and reassess over the next two earnings reports. The upside case is multiple expansion from depressed levels, but downside is asymmetric if credit costs rise or ADR/regulatory risk resurfaces; avoid uncovered short-dated calls.
• Do not act on NNOX from this item: its inclusion is promotional and carries no company-specific operating update. Treat any price strength tied to the marketing copy as liquidity-driven rather than a validated catalyst.